kabutan

Japan Tissue Engineering Co., Ltd.(7774) Summary

7774
TSE Growth
Japan Tissue Engineering Co., Ltd.
534
JPY
-3
(-0.56%)
Apr 28, 3:30 pm JST
3.35
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
4.12
Yield
ー%
Margin Trading Ratio
51.80
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
539 JPY 3.38 USD
Previous Close Apr 27
537 JPY 3.36 USD
High Apr 28, 9:41 am
548 JPY 3.43 USD
Low Apr 28, 12:38 pm
532 JPY 3.34 USD
Volume
81,400
Trading Value
0.04B JPY 0.27M USD
VWAP
537.73 JPY 3.38 USD
Minimum Trading Value
53,400 JPY 335 USD
Market Cap
0.02T JPY 0.14B USD
Number of Trades
188
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
391
1-Year High Dec 30, 2025
8,480
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 545,200 778,100 1.43
Apr 17, 2026 470,700 747,100 1.59
Apr 10, 2026 487,700 767,200 1.57
Apr 3, 2026 516,000 799,700 1.55
Mar 27, 2026 449,800 730,600 1.62
Company Profile
Japan Tissue Engineering Co., Ltd. is a regenerative medicine venture. The company develops autologous cultured epidermis and cartilage, among other products. It became a subsidiary of Teijin through a tender offer.
Sector
Precision Instruments
Japan Tissue Engineering Co., Ltd. focuses on the development, manufacturing, and sales of regenerative medicine products, as well as contracted regenerative medicine services for development and manufacturing, and research and development support. The company has five products: JACE (autologous cultured epidermis), JACC (autologous cultured cartilage), NEPIC (autologous cultured corneal epithelium), OCULAR (autologous cultured oral mucosal epithelium), and JASMINE (autologous cultured epidermis containing melanocytes). In its contracted regenerative medicine business, the company provides CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) services. The research and development support business offers the LabCyte series of human cultured tissues. As new pipelines, the company is working on the development of allogeneic cultured epidermis and CAR-T cell therapies. Japan Tissue Engineering Co., Ltd. is a member of the Teijin Group.